Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PP2PP3_ModeratePP5_Very_Strong
The NM_001018005.2(TPM1):c.644C>T(p.Ser215Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,613,842 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. S215S) has been classified as Likely benign.
TPM1 (HGNC:12010): (tropomyosin 1) This gene is a member of the tropomyosin family of highly conserved, widely distributed actin-binding proteins involved in the contractile system of striated and smooth muscles and the cytoskeleton of non-muscle cells. Tropomyosin is composed of two alpha-helical chains arranged as a coiled-coil. It is polymerized end to end along the two grooves of actin filaments and provides stability to the filaments. The encoded protein is one type of alpha helical chain that forms the predominant tropomyosin of striated muscle, where it also functions in association with the troponin complex to regulate the calcium-dependent interaction of actin and myosin during muscle contraction. In smooth muscle and non-muscle cells, alternatively spliced transcript variants encoding a range of isoforms have been described. Mutations in this gene are associated with type 3 familial hypertrophic cardiomyopathy and dilated cardiomyopathy 1Y. [provided by RefSeq, Jun 2022]
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
?
PM1 - Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 8 uncertain in NM_001018005.2
PM2
?
PM2 - Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium
Very rare variant in population databases, with high coverage;
PP2
?
PP2 - Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease
Missense variant where missense usually causes diseases, TPM1
PP3
?
PP3 - Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)
MetaRNN computational evidence supports a deleterious effect, 0.885
PP5
?
PP5 - Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation
Variant 15-63062219-C-T is Pathogenic according to our data. Variant chr15-63062219-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 31883.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr15-63062219-C-T is described in Lovd as [Pathogenic].
Likely pathogenic, criteria provided, single submitter
clinical testing
GeneDx
Apr 12, 2023
Not observed at significant frequency in large population cohorts (gnomAD); Published in vitro functional studies demonstrated that p.(S215L) caused significantly reduced actin binding and increased calcium sensitivity, thus affecting the contractile properties of the tropomyosin protein (Gupte et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18403758, 23204897, 23700264, 26936621, 27600940, 25607779, 27532257, 29121657, 25548289, 31737537, 33673806, 34011823, 36896133, 36158814) -
Likely pathogenic, no assertion criteria provided
provider interpretation
Stanford Center for Inherited Cardiovascular Disease, Stanford University
Aug 17, 2016
- -
not provided, no classification provided
curation
Leiden Muscular Dystrophy (TPM1)
Apr 15, 2012
- -
Cardiomyopathy Pathogenic:2
Likely pathogenic, criteria provided, single submitter
clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Aug 01, 2017
- -
Likely pathogenic, no assertion criteria provided
literature only
Evolutionary and Medical Genetics Laboratory, Centre for Cellular and Molecular Biology
-
- -
Hypertrophic cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitter
clinical testing
Invitae
Jan 16, 2024
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 215 of the TPM1 protein (p.Ser215Leu). This variant is present in population databases (rs199476316, gnomAD 0.0009%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (HCM) (PMID: 18403758, 23204897, 25607779, 27600940). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 31883). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects TPM1 function (PMID: 23700264, 25548289). For these reasons, this variant has been classified as Pathogenic. -
Likely pathogenic, criteria provided, single submitter
clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Nov 02, 2020
The p.Ser215Leu variant in TPM1 has been reported in at least 7 individuals with HCM and segregated with disease in 6 individuals from 3 families (Morita 2008 PMID: 18403758, Rangaraju 2012 PMID: 23204897, Selvi Rani 2015 PMID: 25607779, Cecconi 2016 PMID: 27600940, Walsh 2017 PMID: 27532257, Viswanathan 2017 PMID: 29121657, Bales 2016 PMID: 26936621). In at least three families with early onset disease, this variant was identified in conjunction with a second pathogenic variant associated to cardiomyopathy, and one individual had cardiomyopathy while only harboring the second variant and not the p.Ser215Leu variant. This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 31883) and has also been identified in 0.0009% (1/113564) of European chromosomes by gnomAD (https://gnomad.broadinstitute.org/). In vitro functional studies provide some evidence that this variant impacts protein function (Gupte 2015 PMID: 25548289); and computational prediction tools and conservation analyses suggest that this variant may impact the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant hypertrophic cardiomyopathy. ACMG/AMP Criteria applied: PM2_supporting, PS4_Moderate, PP3, PS3_Supporting, PP1_Moderate. -
Likely pathogenic, criteria provided, single submitter
clinical testing
Blueprint Genetics
Sep 28, 2015
- -
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter
clinical testing
Ambry Genetics
May 07, 2020
The p.S215L pathogenic mutation (also known as c.644C>T), located in coding exon 7 of the TPM1 gene, results from a C to T substitution at nucleotide position 644. The serine at codon 215 is replaced by leucine, an amino acid with dissimilar properties. This variant has been reported in multiple individuals with hypertrophic cardiomyopathy in the heterozygous and compound heterozygous state, and has been found to co-segregate with disease (Morita H et al. N. Engl. J. Med. 2008;358:1899-908, Rangaraju A et al. Exp Clin. Cardiol. 2012;17:26-9, Selvi Rani D et al. DNA Cell Biol. 2015;34:350-9, Bales ND et al. Pediatr. Cardiol. 2016;37:845-51). The patients who harbored this variant in the compound heterozygous state were noted to be more severely affected (Selvi Rani D et al. DNA Cell Biol. 2015;34:350-9). An in vitro functional study showed close to a two-fold decrease in tropomyosin binding affinity for actin with hypersensitivity to calcium (Gupte TM et al. J. Biol. Chem. 2015;290:7003-15). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -